Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 8, 2012, Pages 1293-1302

  Koestler, Devin C ^a   Marsit, Carmen J ^a   Christensen, Brock C ^a   Accomando, William ^c   Langevin, Scott M ^b,c   Houseman, E Andres ^d   Nelson, Heather H ^e   Karagas, Margaret R ^a   Wiencke, John K ^f   Kelsey, Karl T ^b,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; BLADDER CANCER; BLOOD; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; FEMALE; GENETIC VARIABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LEUKOCYTE; MALE; METHYLATION; NEOPLASM; NONHEMATOPOIETIC CANCER; OVARY CANCER; PRIORITY JOURNAL;

ADULT; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOCYTES; MALE; NEOPLASMS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84864822325     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0361     Document Type: Article

References (55)

1. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, et al. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genetics 2007;3:e181. [cited 2011 Dec 15]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2041996/.
2. Sincic N, Herceg Z. DNA methylation and cancer: ghosts and angels above the genes. Curr Opin Oncol 2011;23:69-76.
3. Cheung HH, Lee TL, Rennert OM, Chan WY. DNA methylation of cancer genome. Birth Defects Res C 2009;87:335-50.
4. Cui HM. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers 2007;23:105-12.
5. Wilhelm-Benartzi CS, Koestler DC, Houseman EA, Christensen BC, Wiencke JK, Schend AR, et al. DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis 2010;31:1972-6.
6. Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J, et al. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics 2011;6:1248-56.
7. Christensen BC, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, Roelofs CR, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009;69:227-34.
8. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, et al. Examination of aCpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006;66:10621-9. (Pubitemid 44799786)
9. Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrench MR, Yeh RF, et al. Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis 2009;30:416-22.
10. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 2008;3:e2656.
11. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 2009;3:e8274. [cited 2011 Dec 15]. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone. 0008274.
12. Wang L, Aakre JA, Jiang R, Marks RS, Wu Y, Chen J, et al. Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. J Thorac Oncol 2010;5:778-85.
13. Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, Kelsey KT. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol 2011;29:1133-9.
14. Pedersen KS, Bamlet WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, et al. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One 2011;6:e18223. [cited 2011 Dec 15]. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0018223.
15. Langevin SM, Koestler DC, Christensen BC, Butler RA, Wiencke JK, Nelson HH, et al. Peripheral blood DNA methylation profiles are predictive of head and neck squamous cell carcinoma: an epigenome- wide association study. Epigenetics 2012;7:291-9.
16. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66. (Pubitemid 37328861)
17. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14:65-76.
18. Applebaum KM, McClean MD, Nelson HH, Marsit CJ, Christensen BC, Kelsey KT. Smoking modifies the relationship between XRCC1 haplotypes and HPV6-negative head and neck squamous cell carcinoma. Int J Cancer 2009;124:2690-6.
19. Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a US population. Environ Health Perspect 1998;106:1047-50. (Pubitemid 28419791)
20. Wallace K, Kelsey KT, Schned A, Morris JS, Andrew AS, Karagas MR. Selenium and risk of bladder cancer: a population-based case-control study. Cancer Prev Res 2009;2:70-73.
21. Rocke DM. On the beta transformation family. Technometrics 1993;35:72-81.
22. Koestler DC, Marsit CJ, Christensen BC, Karagas MR, Bueno R, Sugarbaker DJ, et al. Semi-supervised recursively partitioned mixture models for identifying cancer subtypes. Bioinformatics 2010;26:2578-85.
23. Houseman EA, Christensen BC, Yeh RF, Marsit CJ, Karagas MR, Wrench MR, et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising a mixture of beta distributions. BMC Bioinformatics 2008;9:365. [cited 2011 Dec 15]. Available from: http://www.biomedcentral.com/1471-2105/9/365.
24. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrench MR, Wiemels JL, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 2009;5:e1000602. [cited 2011 Dec 15]. Available from: http://www.plosgenetics.org/article/info:doi/10.1371/ journal.pgen.1000602.
25. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011;103:143-53.
26. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2011;22:271-82.
27. Banister CE, Koestler DC, Maccani MA, Padbury JF, Houseman EA, Marsit CJ. Infant growth restriction is associated with distinct patterns of DNA methylation in human placentas. Epigenetics 2011;6:920-7.
28. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagal Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-20. (Pubitemid 351630053)
29. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006;25:2105-12.
30. Rui L, Schmitz R, Ceribelli M, Staudt LM. Malignant pirates of the immune system. Nat Immunol 2011;12:933-40.
31. Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010;125:272-83.
32. Alhamarneh O, Amarnath SMP, Stafford ND, Greenman J. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer. Head Neck 2008;30:251-61. (Pubitemid 351251710)
33. Schott AK, Pries R, Wollenberg B. Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med 2010;26:67-75.
34. Peng DJ, Liu R, Zou W. Regulatory T-cells in ovarian cancer. J Oncol 2012;2012:345164.
35. Alevaro AB, Montagna MK, Craveiro V, Liu L, Mor G. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol 2012;67:256-65.
36. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24:95-105. (Pubitemid 40576066)
37. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002;110:693-702. (Pubitemid 35423170)
38. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009;15:3325-32.
39. Whiteside TL. Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep 2001;3:46-55.
40. Bartlett JM, Langdon SP, Scott WN, Love SB, Miller EP, Katsaros D, et al. Transforming growth factor-β isoform expression in human ovarian tumours. Eur J Cancer 1997;33:2397-403. (Pubitemid 28129184)
41. Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86. (Pubitemid 38032120)
42. Cazac BB, Roes J. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity. 2000;13:443-51.
43. BioGPS. Available from: http://biogps.gnf.org.
44. HaemAtlas. Available from: http://dil.t1dbase.org/page/HaemAtlasView.
45. Fritsche G, Nairz M, Werner ER, Barton HC, Weiss G. Nramp1-functionality increases iNOS expression via repression of IL-10 formation. Eur J Immunol 2008;38:3060-7.
46. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor 2010;21:331-44.
47. Tan YV, Abad C, Lopez R, Dong H, Liu S, Lee A, et al. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci 2009;106:2012-7.
48. Huber C, Mrtensson A, Bokoch GM, Nemazee D, Gavin AL. Fgd2, a cdc42-specific exchange factor expressed by antigen-presenting cells, localizes to early endosomes and active membrane ruffles. J Biol Chem 2008;283:34002-12.
49. Tong CC, Kao J, Sikora AG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res. 2012 Mar 28. [Epub ahead of print].
50. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. (Pubitemid 36077915)
51. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-in fi ltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108:415-20. (Pubitemid 351174290)
52. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci 2005;102:18538-43. (Pubitemid 43011261)
53. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
54. Soygur T, Beduk Y, Yaman O, Yllmaz E, Tokgoz G, Gogus O. Analysis of the peripheral blood lymphocyte subsets in patients with bladder cancer. Urology 1999;53:88-91. (Pubitemid 29016620)
55. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012;13:86.